

Pennsaid® (diclofenac sodium) – First-time generic

- On May 10, 2022, Apotex launched an <u>AB-rated</u> generic version of Horizon's <u>Pennsaid</u> (diclofenac sodium) 2% topical solution.
- Pennsaid is approved for the treatment of the pain of osteoarthritis (OA) of the knee(s).
- Diclofenac sodium topical solution is also available as a <u>1.5%</u> formulation indicated for the signs and symptoms of OA of the knee(s).
- Pennsaid carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.